All In Biotech

Company

Bracco

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

44

19 still marketed

Novel approvals

13

Approvals since 2021

6

Originals and new uses

Phase 3 trials

12

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

  • Bracco Diagnostics, IncIndustry

    NCT06400004 · 106 participants (planned) · Start Jul 10, 2024 · Primary completion Aug 29, 2026

    Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]; Lumason · For: Heart Diseases

    Sites: West Hills, California; Atlanta, Georgia; Boston, Massachusetts · 6 sites in all

Marketed drugs (19)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.